Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 P
PROpel, a phase 3 clinical trial, looked at whether combining olaparib with abiraterone delays the progression of patients' cancer compared with placebo plus abiraterone. Patients with or without pain symptoms associated with metastatic castration-resistant prostate cancer were eligible for enrolment into the trial. Results showed that olaparib plus abiraterone reduced the risk of disease progression and death, with a larger benefit observed in patients without or with mild pain symptoms than in those with pain symptoms.
Authors
- Jae Young Joung (ORCID: https://orcid.org/0000-0003-2954-1663)
- Çağatay Arslan (ORCID: https://orcid.org/0000-0002-3783-7432)
- Christian Poehlein (ORCID: https://orcid.org/0000-0002-3348-3059)
- David McGuinness (ORCID: https://orcid.org/0000-0003-2947-2047)
- Arnold Degboe
- Niven Mehra (ORCID: https://orcid.org/0000-0002-4794-1831)
- Andrew J. Armstrong (ORCID: https://orcid.org/0000-0001-7012-1754)
- Fred Saad (ORCID: https://orcid.org/0000-0003-2986-5617)
- Giuseppe Procopio (ORCID: https://orcid.org/0000-0002-2498-402X)
- João Daniel Guedes
- Noel W. Clarke (ORCID: https://orcid.org/0000-0001-7776-8059)
- Oliver A. Sartor (ORCID: https://orcid.org/0000-0002-8777-7343)
- Mikio Sugimoto (ORCID: https://orcid.org/0000-0001-9266-782X)
- Mototsugu Oya (ORCID: https://orcid.org/0000-0002-2048-4263)
- Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
- Friederike Schlürmann
- Francis Parnis
- Emma Brown
Institutions
- AstraZeneca (United Kingdom) (GB)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Izmir University (TR)
- Radboud University Nijmegen (NL)
- Duke University (US)
- Keio University (JP)
- Salford Royal NHS Foundation Trust (GB)
- Radboud University Medical Center (NL)
- University Hospital Southampton NHS Foundation Trust (GB)
- Centre Hospitalier de Cornouaille (FR)
- National Cancer Center (KR)
- The Christie NHS Foundation Trust (GB)
- Kagawa University Hospital (JP)
- Centre Hospitalier de l’Université de Montréal (CA)
- AstraZeneca (United States) (US)
- Hospital de Base (BR)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Carolina Urologic Research Center (US)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1016/j.euo.2024.09.013
- Citations
- 12
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 5.03
Funders
- AstraZeneca